100 Great Meadow Road
4 articles with Modis
“This transaction advances Zogenix’s mission to become a leading rare disease pharmaceutical company by adding MT1621 to our pipeline of late-stage Fintepla programs,” stated Stephen J. Farr, president and chief executive officer of Zogenix.
Modis Therapeutics Announces that MT1621 Receives Breakthrough Therapy Designation from FDA for the Treatment of TK2 Deficiency
Designation Based on Compelling Data from Initial Clinical Studies and High Unmet Need in Thymidine Kinase 2 Deficiency
Presentation by Dr. Michio Hirano on Mitochondrial DNA Depletion Disorders will Highlight Clinical Data on Treatment of Thymidine Kinase 2 Deficiency with Deoxynucleoside Therapy.
Modis Therapeutics, Inc., a company developing medicines for patients with rare genetic diseases, announced today a $30M Series A investment